Archive for the ‘Heart Issues’ Category

Vaccine-Induced Thrombocytopenia & Thrombosis

https://www.nejm.org/doi/full/10.1056/NEJMoa2109908?

Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis

List of authors.

  • Sue Pavord, F.R.C.Path., 
  • Marie Scully, M.D., 
  • Beverley J. Hunt, M.D., 
  • William Lester, M.D., 
  • Catherine Bagot, M.D., 
  • Brian Craven, M.B., B.Ch., 
  • Alex Rampotas, M.R.C.P., 
  • Gareth Ambler, Ph.D., 
  • and Mike Makris, M.D.

Abstract

BACKGROUND

Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a new syndrome associated with the ChAdOx1 nCoV-19 adenoviral vector vaccine against severe acute respiratory syndrome coronavirus 2. Data are lacking on the clinical features of and the prognostic criteria for this disorder.

METHODS

We conducted a prospective cohort study involving patients with suspected VITT who presented to hospitals in the United Kingdom between March 22 and June 6, 2021. Data were collected with the use of an anonymized electronic form, and cases were identified as definite or probable VITT according to prespecified criteria. Baseline characteristics and clinicopathological features of the patients, risk factors, treatment, and markers of poor prognosis were determined.

RESULTS

Among 294 patients who were evaluated, we identified:

  • 170 definite cases of VITT
  • 50 probable cases of VITT
  • All the patients had received the first dose of ChAdOx1 nCoV-19 vaccine and presented 5 to 48 days (median, 14) after vaccination. The age range was 18 to 79 years (median, 48), with no sex preponderance and no identifiable medical risk factors
  • Overall mortality was 22%
  • The odds of death increased by a factor of
    • 2.7 (95% confidence interval [CI], 1.4 to 5.2) among patients with cerebral venous sinus thrombosis
    • 1.7 (95% CI, 1.3 to 2.3) for every 50% decrease in the baseline platelet count
    • 1.2 (95% CI, 1.0 to 1.3) for every increase of 10,000 fibrinogen-equivalent units in the baseline d-dimer level
    • 1.7 (95% CI, 1.1 to 2.5) for every 50% decrease in the baseline fibrinogen level
    • Multivariate analysis identified the baseline platelet count and the presence of intracranial hemorrhage as being independently associated with death
    • observed mortality was 73% among patients with platelet counts below 30,000 per cubic millimeter and intracranial hemorrhage
CONCLUSIONS

The high mortality associated with VITT was highest among patients with a low platelet count and intracranial hemorrhage. Treatment remains uncertain, but identification of prognostic markers may help guide effective management. (Funded by the Oxford University Hospitals NHS Foundation Trust.)

_____________________

**Comment**

The numbers don’t lie.  

A majority of these “vaccinated” patients had VITT which explains what is happening in reality – blood clotting issues.  

  • We’ve been warned by a Canadian doctor doing D-dimer tests on his “vaccinated” patients that 62% show microscopic blood clotting.
  • A pathologist also states these injections cause severe inflammation due to the “spike protein” which is a dangerous toxin that crosses the blood-brain barrier and disrupts blood vessels throughout the body and brain.  He also reiterates that these injections are not “vaccines.”

Please notice the overall mortality of 22% and significant increased odds of death on these fully “vaccinated” individuals that have been told ad nauseam that these injections will be protective and keep you from hospitalization and death.

For a mounting list of adverse reactions and death (with many examples of blood clotting & cardiovascular issues – even in young people):  https://madisonarealymesupportgroup.com/2020/12/21/warning-3150-injuries-in-1st-week-of-covid-vaccines-among-american-healthcare-workers-pregnant-women-included/

Lyme Carditis 2021 Update

https://lymediseaseassociation.org/blogs/lda-guest-blogs/adrian-baranchuk-md-guest-blog/

Adrian Baranchuk, MD, Guest Blog – Lyme Carditis 2021 Update

LDA Guest Blogger

Adrian_Baranchuk_Photo_2020

Adrian Baranchuk MD, FACC, FRCPC, FCCS, FSIAC is Professor of Medicine at Queen’s University, Kingston, Ontario, Canada. He is Editor-in-chief, Journal of Electrocardiology; Vice President, International Society of Holter and Non-Invasive Electrocardiology (ISHNE); Secretary, Interamerican Society of Cardiology (SIAC); Co-Director, ECG University; Past President, International Society of Electrocardiology (ISE); and Director, NET-Heart Project (Neglected Tropical Diseases and other Infectious Diseases affecting the Heart).

Lyme Carditis: Update 2021. An Evasive Diagnosis in the Time of COVID-19

Adrian Baranchuk MD, FACC, FRCPC, FCCS, FSIAC; Chang (Nancy) Wang MSc (c), MD
Department of Medicine, Kingston Health Science Center, Kingston, Ontario, Canada

Lyme disease (LD) is a tick-borne bacterial infection caused by Borrelia burgdorferi. Lyme carditis (LC) is an early-disseminated manifestation of LD, most commonly manifesting as a complete “shut-down” of the electrical system (high-degree atrioventricular block (AVB)) that can evolve rapidly over minutes, hours, or days producing severe symptoms like fainting, palpitations, shortness of breath, extreme dizziness, or sudden death (1-2).

Other cardiovascular manifestations include alterations of the “motor” of the heart (sinus node disease) (3), a disorganization of the cardiac rhythm that increases the risk of stroke (atrial fibrillation) (2), lesion in the distal cables of the heart (bundle branch blocks) (4), and different degrees of inflammation of the layers of the cardiac walls (myocarditis, pericarditis, and endocarditis) (2). Some of these manifestations could be so severe that a total dysfunction of the cardiac function occurs in a matter of hours, and the patient may die even if admitted to the best ICU in the world.

The initial symptoms of LD can be mistaken by other common infections or allergic reactions. Delayed diagnosis is one of the most important risk factors to serious LD presentations including LC in all its forms. The good news is that prompt diagnosis and appropriate antibiotic therapy links to a much better prognosis. In addition, we now know that when appropriately treated with antibiotics according to guidelines (2); there is no evidence of residual disease in the heart (5).

Most conduction abnormalities caused by LC resolve with appropriate antibiotic therapy (2).

The current COVID-19 pandemic is posing a new challenge in the diagnosis of LD. There are lots of overlapping symptoms such as: fever, malaise, generalized pain, lack of energy, etc. During these times, one would advise on ruling out COVID-19 first before embarking on any other test. However, what could we recommend in terms of confirming or ruling out LD, specifically during these challenging times?

Learning how to recognize the many presentations of LD from a clinical point of view has been published several times. It is especially important to ask about outdoor activities, history of tick bites, tick removal and dermatological rashes (remember that the classic “bull eye” is only present in about 40% of cases). Extensive dermatologic examination may be necessary. Residence in an endemic region for LD is essential for risk stratification, as these recommendations should be encouraged in all ED and family doctor offices in areas of high prevalence.

Once the diagnosis is suspected, specific interrogation should be directed to cardiovascular symptoms such as: dizziness, palpitations, fainting or near fainting, chest pain and shortness of breath. If the patient recognizes any of these symptoms, along with any other factors suggesting LD, a 12-lead ECG (the simple and unexpensive electrocardiogram) should be performed (2). Any evidence of electrical disturbance should prompt admission in hospital for a course of IV antibiotics while waiting the results of serological tests.

On the other hand, in patients presenting with unexpected high-degree AV block, clinical suspicion for LC can be assessed using the validated risk score called SILC (Suspicious Index in Lyme carditis) (6) where the acronym COSTAR(Constitutional symptoms, Outdoor activities/endemic region, Sex male, Tick bite, Age > 50, Rash) may help in determining the risk of presenting early disseminated LC.

In summary, use your clinical tools to suspect LD in the context of COVID-19 pandemic, order serological tests when appropriate, and remember to check for cardiovascular complications with a history, physical, and ECG. If evidence of LC, admit the patient to hospital with continuous cardiac monitoring and appropriate IV antibiotics. Decision for permanent pacemaker implantation should wait until completion of antibiotics as heart block in LC is often reversible. Most patients maintain normal rhythm on long-term follow-up. Avoiding unnecessary implants is crucial as most of these patients are young and active individuals.

References
1. Wan D, Blakely C, Branscombe P, Suarez-Fuster L, Glover B, Baranchuk A. Lyme Carditis and High-degree Atrioventricular Block. Am J Cardiol 2018; 26(5): 233-239
2. Yeung C, Baranchuk A. Diagnosis and Treatment of Lyme Carditis. J Am Coll Cardiol 2019; 73(6): 717-726
3. Gazendam N, Yeung C, Baranchuk A. Lyme carditis presenting as sick sinus syndrome. J Electrocardiol 2020; 59: 65-67
4. Maxwell N, Dryer M, Baranchuk A, Vinocur M. Phase 4 Block of the Right Bundle Branch Suggesting His-Purkinje System Involvement in Lyme Carditis. HeartRhythm Case Reports. 2020; 7(2): 112-116
5. Wang C, Baranchuk A. Long-term evolution of patients treated for early disseminated Lyme carditis. Third prize at the ICE 2021 (International Congress on Electrocardiology)
6. Besant G, Wan D, Yeung C, Blakely C, Branscombe P, Suarez-Fuster L, Redfearn D, Simpson C, Abdollah H, Glover B, Baranchuk A. Suspicious Index in Lyme Carditis (SILC): Systematic Review and Proposed New Risk Score. Clin Cardiol 2018; 41(12):1611-1616

______________________

For more:

Vector Biology: Connecting Human Health, Animal Health & the Environment

Vector Biology: Connecting human health, animal

health and the environment

Mount Allison University

Lyme Research Network

Vett Lloyd, Chris Zinck, Samantha Bishop

Vector-Biology-Connecting-human-health-animal-health-and-the-environment-Vett-Lloyd(1)   Slides Here 

________________________

Important Findings:

Donor 1
▪ Borrelia was detected by nPCR, FISH and protein was detected by immunohistology in biopsied thoracic artery tissue. It was not detected in the other cardiac tissues.
▪ Borrelia burgdorferi DNA present only at low abundance in connective tissue
▪ These results validate the clinical diagnosis of Lyme disease in this individual, US serology and tick exposure
▪ Limited detection is consistent with aggressive treatment, although Borrelia DNA was detected. Viability cannot be assessed by these methods.
▪ Round body more common than long/spriocheatal forms
▪ The individual is still well, active and healthy

Donor 2
▪ Abundant Borrelia was detected by FISH in the pericardium
▪ Other tissues still to be tested
▪ These results are consistent with tick exposure and US WB but not Canadian serology
▪ Round body more common than long/spriocheatal forms
▪ Involvement of Borrelia infection in donor 2’s heart failure is an important question for the family and for all individuals living in endemic areas

Significance

➢ This study demonstrates that Borrelia DNA can be detected in human tissues using molecular methods

Chronic Bartonella Infections in Animals and Humans: Crypto-Infections Conference

Chronic Bartonella Infections in Animals and Humans

2nd European Crypto-Infections Conference

Catherine McAuley Center, Dublin, Ireland

September 26-27, 2020

Presentation by Bruno B. Chomel, Distinguished Professor of Zoonoses

Department of Population Health and Reproduction,

School of Veterinary Medicine,

University of California, Davis, CA, USA

Bartonella-endocarditis-Dublin-2020-Bruno-Chomel(3)  Slides Here

___________________

For more:

How To Diagnose If Lyme Disease is Affecting the Heart and How to Best Treat it

https://www.bayarealyme.org/blog/how-to-diagnose-if-lyme-disease-is-affecting-the-heart-and-how-to-best-treat-it/  Video Here:  Approx. 35 Min

HOW TO DIAGNOSE IF LYME DISEASE IS AFFECTING THE HEART AND HOW TO BEST TREAT IT

Dr. Baranchuk, Professor of Medicine at Queen’s University in the Division of Cardiology in Ontario Canada

Dr. Baranchuk, Professor of Medicine at Queen’s University in the Division of Cardiology in Ontario Canada, Editor-in-Chief of the Journal of Electrocardiology, Vice-President of the International Society of Holter and Noninvasive Electrocardiology and Secretary of the Inter-American Society of Cardiology, discusses his screening process for identifying Lyme infections in the heart and how to treat these patients without unnecessary pacemakers.

For more: